Management of Endometrial Cancer: French Society of Onco-Gynecology‘s Evaluation through a Delphi Survey

Our aim was to assess the opinion of a panel of experts and obtain a consensus on the management of endometrial cancer in France and French Switzerland. A Delphi survey was carried out among a panel of French and French-speaking Swiss experts. The first questionnaire included 65 questions divided into eight categories: characterization of experts, histo-molecular characteristics and radiological data of endometrial cancer, and management of low-risk, intermediate-risk, intermediate–high-risk, high-risk, and metastatic cancers. The experts were asked to reply on a 9-point scale, both on the validity and the clarity of each question. After the answers were analyzed, a second questionnaire was sent to the same experts. The study took place between December 2021 and March 2022. Further, 58 (57.4%) of the 101 experts responded in the first round, and 39 recommendations were obtained (60%). Six questions were voted redundant and 20 discordant. These questions were reformulated, and, at the end of the second round, 17 recommendations were validated (85%). In total, the study presents an analysis of 56 questions and related responses. Expert advice helps to clarify non-consensual issues, standardize the management of endometrial cancer, and optimize clinical practices.

[1]  J. Ledermann,et al.  Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Pollock,et al.  p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial , 2022, Modern Pathology.

[3]  D. Juneja,et al.  Delphi methodology in healthcare research: How to decide its appropriateness , 2021, World journal of methodology.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  Cyrus Chargari,et al.  ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.

[6]  G. Turashvili,et al.  Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging , 2020, JAMA surgery.

[7]  H. Putter,et al.  Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Köbel,et al.  p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.

[9]  J. Persson,et al.  Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial)-the final step towards a paradigm shift in surgical staging. , 2019, European journal of cancer.

[10]  G. Bogani,et al.  Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. , 2019, Gynecologic oncology.

[11]  J. Monteil,et al.  Para-aortic Lymph Node Invasion in High-risk Endometrial Cancer: Performance of 18FDG PET-CT , 2019, AntiCancer Research.

[12]  Kathleen R. Cho,et al.  International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  M. Ohmichi,et al.  The diagnostic accuracy of fluorodeoxyglucose-positron emission tomography/computed tomography and sentinel node biopsy in the prediction of pelvic lymph node metastasis in patients with endometrial cancer , 2018, Medicine.

[14]  H. Putter,et al.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.

[15]  M. Munsell,et al.  A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. , 2017, Gynecologic oncology.

[16]  A. Ivanova,et al.  A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. , 2017, The Lancet. Oncology.

[17]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[18]  Pascale Grosclaude,et al.  Survie des personnes atteintes de cancer en France 1989-2007: étude à partir des registres des cancers du réseau Francim , 2013 .

[19]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[20]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[21]  K. Kinkel,et al.  Staging endometrial cancer: Role of magnetic resonance imaging , 2001, Journal of magnetic resonance imaging : JMRI.

[22]  D. Hunter,et al.  Qualitative Research: Consensus methods for medical and health services research , 1995 .

[23]  N. Dalkey,et al.  An Experimental Application of the Delphi Method to the Use of Experts , 1963 .